WO2019111415A1 - カチオン化ベシクル及びその組成物 - Google Patents
カチオン化ベシクル及びその組成物 Download PDFInfo
- Publication number
- WO2019111415A1 WO2019111415A1 PCT/JP2017/044249 JP2017044249W WO2019111415A1 WO 2019111415 A1 WO2019111415 A1 WO 2019111415A1 JP 2017044249 W JP2017044249 W JP 2017044249W WO 2019111415 A1 WO2019111415 A1 WO 2019111415A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cationized
- vesicle
- active ingredient
- cosmetic
- vesicles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/556—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
Definitions
- the present invention relates to a cationized vesicle which has been cationized using a novel cationization substance and a process for producing the same.
- the present invention relates to the use of cationized vesicles as cosmetics.
- Vesicles are vesicles enveloped by bilayer membranes formed by the self-association of amphiphilic molecules, and in particular those made of phospholipid bilayers similar to cell membranes are called liposomes.
- Various substances can be encapsulated in vesicles (liposomes). Liposomes can be used to deliver substances encapsulated in cells into cells, and research and development are being conducted as carriers in drug delivery technology (DDS: drug delivery system).
- DDS drug delivery technology
- Patent 5623076 describes a vesicle composition using lysophospholipid and a skin external preparation comprising the vesicle dispersion composition.
- JP 2012-206948 describes a liposome composition which is stable even in an acidic region, and a cosmetic and a skin external preparation containing the composition.
- Japanese Patent Application Laid-Open Nos. 2007-176820 and 2007-176821 are directed to producing a cosmetic using a powdered phospholipid composition which can be dispersed in an aqueous medium to obtain a stable liposome. Have been described.
- compositions for topical application such as cosmetics
- devices have been developed to improve the penetration of the active ingredient into cells.
- the cationization is to charge the substance positively. Since the skin is negatively charged, positive substances are easily adsorbed.
- Patent No. 4950419 and Patent No. 5220546 have devised components for promoting the intracellular penetration of substances into cells of skin or hair for the purpose of cosmetic use. Liposomes have been described.
- JP-A-2006-35036 discloses an oil-based drug-containing particle in which an oil-based drug is contained as oil droplets in a water-soluble solid matrix and further contains an emulsified substance that exhibits cationicity in water. Is described.
- Patent Document 8 describes a cationized vesicle containing a mineral as an active ingredient of a cosmetic.
- a substance to be cationized cationized hyaluronic acid excellent in adsorption to skin and hair is considered to be preferable.
- Patent 5623076 Vesicle composition and external preparation for skin
- JP 2012-206948 Liposome composition, cosmetic using the same, external preparation for skin and method for producing the same
- JP 2007-176820 Powder-like phospholipid composition
- JP 2007-176821 Powder-like phospholipid composition
- Patent No. 4950419 Liposome containing cationic polymer to promote intracellular penetration
- the cationized vesicle is easy to be adsorbed to the skin, and when the cosmetic active ingredient is used by being incorporated, the ingredient can be efficiently delivered to the skin, and thus it is a composition excellent as a cosmetic material. It is an object of the present invention to provide cationized vesicles which are highly stable and can further contain not only minerals but also various other cosmetic active ingredients.
- the present inventors conducted studies on the composition of a cationized polymer that cationizes vesicles. And, by using the new cationized polymer in which the composition of the conventional cationized polymer is changed, the stability of the cationized vesicle is improved, the types of inclusions are diversified, and the concentration of the inclusions is increased. Completed the invention.
- the present invention relates to a cationized vesicle for use by being added to a cosmetic, which is cationized with a novel cationized polymer.
- the present invention also relates to a method of cationizing vesicles using the novel cationized polymers.
- the invention also relates to a process for the production of cationized vesicles using the novel cationized polymers.
- the invention also relates to novel cationized polymers.
- the cationized polymer contains 2-methacryloyloxyethyl phosphorylcholine and a cationic monomer, and the proportion of the cationic monomer in the cationized polymer is preferably 50% or more.
- the cationic monomer is (2-hydroxy-3-methacryloyloxypropyl) trimethyl ammonium chloride, or 2- (methacryloyloxy) ethyl trimethyl ammonium colloid, or N, N-dimethylaminoethyl acrylate benzyl chloride quaternary salt Is preferred.
- the cationized vesicles may be either unilamellar vesicles or multilamellar vesicles.
- the present invention also relates to an active ingredient-containing cationized vesicle in which a cosmetic active ingredient is retained in the cationized vesicle.
- the active ingredient is preferably a negatively charged substance, and examples thereof include minerals, amino acids, anionic surfactants, vitamins (eg, vitamin C and its derivatives) and the like.
- the present invention also relates to the cationized vesicle, wherein the zeta potential is +20 mV or more.
- the present invention also relates to the above-mentioned active ingredient-containing cationized vesicle having a zeta potential of +20 mV or more.
- the invention also relates to the said lyophilised said cationized vesicles.
- the present invention also relates to the freeze-dried active ingredient-containing cationized vesicle.
- the present invention also relates to a cosmetic containing the cationized vesicle, or the active ingredient-containing cationized vesicle, or the freeze-dried cationized vesicle or the active ingredient-containing cationized vesicle.
- the cosmetic may further contain a substance derived from a natural product.
- the present invention is also a topically applied cosmetic having adsorptivity to skin and hair, wherein said cationized vesicle, or said active ingredient-containing cationized vesicle, or said freeze-dried cationized
- the present invention relates to a cosmetic comprising a vesicle or an active ingredient-encapsulated vesicle.
- the present invention is also directed to applying to the skin or hair a cosmetic comprising the cationized vesicle, or the active ingredient-incorporated cationized vesicle, or the freeze-dried cationized vesicle or active ingredient-incorporated cationized vesicle. It relates to the method of cosmetic treatment.
- the beauty treatment method may be performed at a salon or at home.
- the cationized vesicles of the present invention have excellent skin permeability and skin permeability, and are low in skin irritation, so they are suitable for being incorporated into functional cosmetics.
- the cationized vesicle of the present invention is improved in stability as compared with the conventionally known ones, and the concentration of the substance which can be contained (for example, the active ingredient such as mineral) is high, and the substance which can be further contained is diversified. ing.
- Vesicles are formed as a spherical structure with a closed bilayer membrane with the hydrophobic tail inside and the hydrophilic head outward due to the spontaneous association of amphiphilic molecules in water. Ru.
- Single lamellar vesicles also called “monolamellar vesicles” are spherical vesicles composed of one lipid bilayer membrane.
- MLV multi-lamellar vesicle
- Liposomes A large number of amphiphilic molecules capable of forming vesicles exist, but especially those made of phospholipids are called liposomes.
- Vesicle is a generic term for vesicles consisting of phospholipids and surfactants. Liposomes are like capsules having the same membrane as skin cells and are excellent in biocompatibility.
- the phospholipid membrane is composed of egg yolk, soybean-derived phospholipid or glycerophospholipid, or cyclic phosphatidic acid, and is originally negatively charged.
- the phospholipid may be either synthetic or commercially available.
- cholesterol and phospholipid can be combined for the purpose of adjusting the hardness and permeability of the lipid bilayer membrane comprising phospholipid.
- the vesicles can be prepared by conventional preparation methods generally known as liposome preparation methods.
- Cationization is the positive charging of a substance. Since the cationized vesicles are positively charged, they are expected to be more easily adsorbed and permeated to the skin as compared to non-cationized vesicles. In the present invention, it is desirable to cationize the vesicles to such an extent that such effects can be obtained. Specifically, it is preferable that the zeta potential of the cationized vesicle is +20 mv or more, more preferably +30 mV or more.
- CMLV cationized MLV
- CSLV cationized SLV
- a cationized molecule is used to cationize the vesicles.
- cationized polymers are used as cationized molecules.
- the cationized vesicle is obtained by adding a cationized molecule (cationized polymer) at the time of forming the vesicle to cationize the vesicle.
- the cationized polymer is a high molecular weight substance which is cationized by introducing a cationic group.
- the cationized polymer itself needs to be biocompatible, and in addition, it is preferable to have a moisturizing effect on the skin and the hair.
- a cationized polymer composed of a polymer of 2-methacryloyloxyethyl phosphorylcholine (abbreviation: MPC) and a specific cationic monomer is used.
- MPC is a revolutionary biocompatible material that has the same structure as the cell membrane and a polymerizable structure and has extremely high affinity to living organisms.
- cationic monomers are Blemmer (R) QA: (2-hydroxy-3-methacryloyloxypropyl) trimethyl ammonium chloride; MOETAC: 2- (methacryloyloxy) ethyltrimethylammonium chloride; DMAEA (registered trademark) -BQ: N, N-dimethylaminoethyl acrylate benzyl chloride quaternary salt and the like.
- MPC-Blenmer QA copolymer This is a synthetic polymer consisting of MPC and Blenmer (registered trademark) QA, and the component name (display name) is "Polyquaternium-64".
- a typical commercially available polyquaternium-64 consists of 30% MPC and 70% cationic monomer.
- the cationized polymers of the novel composition produced in the examples are also suitably used.
- One aspect of such a cationized polymer is a cationized polymer consisting of MPC and Blenmer (R) QA.
- Another embodiment is a cationized polymer consisting of MPC and MOETAC.
- Yet another embodiment is a cationic polymer consisting of MPC and DMAEQ (R) BQ.
- the ratio of MPC to cationic monomer in the cationized polymer, and the molecular weight of the cationized polymer can be varied.
- the proportion of the cationic monomer in the cationized polymer is preferably 50% or more, more preferably 55% or more.
- the present inventors have confirmed that cationized vesicles can be produced even if the proportion of cationic monomers is increased to 82%. Moreover, it is preferable that the molecular weight of a cationization polymer is 600,000 or more. The present inventors have confirmed that a cationized vesicle can be produced even with a molecular weight of 2,000,000.
- cationized vesicles in which cosmetic active ingredients are incorporated are added to cosmetics such as lotions, beauty essences, emulsions, creams, shampoos and the like, the components can be efficiently delivered to the skin .
- SLV is suitable for lotions and cosmetic solutions because it is transparent
- MLV is suitable for emulsions and creams because it is milky white.
- the substance which the cationized vesicle contains is suitably selected by the use of cosmetics.
- a negatively charged substance can be incorporated as a cosmetic component.
- cosmetic ingredients to be contained include minerals, amino acids, anionic surfactants, and components having a negative ion such as vitamin C and its derivatives.
- active ingredient inclusion cationized vesicle a cationized vesicle in which a cosmetic active ingredient is retained.
- a deep sea water concentration composition described in JP 2007-217356, a deep sea water described in JP 2000-290159, or a hot water flower extract described in Japanese Patent No. 3967357 is cited.
- Be A deep sea water composition or deep sea water or dried sea water which is a dried product thereof, or a cationized vesicle in which a hot water flower extract is enclosed is herein referred to as a "mineral-containing cationized vesicle".
- the concentration of the NF permeated water it is preferable that the concentration is 14 to 50 times, and the NF permeated water concentrate is in the form of an aqueous solution without precipitates.
- the pore diameter of the above-mentioned nanofilter membrane is preferably 0.1 to 1 nm, and the pressure applied to the membrane is preferably 0.3 to 2.0 MPa.
- a hot water flower extract is a composition comprising an ozonized product of hot water flower obtained by a manufacturing method comprising the following steps (1) to (3): (1) A hot spring flower is crystallized on blue clay with constant temperature and constant humidity to obtain hot water flower, (2) dissolve the hot water flower in an aqueous solvent, and (3) The dissolved product is subjected to ozone oxidation treatment to obtain an ozone oxidized product.
- the hot water flower extract contains (1) sulfate ion 25 to 40,000 mg / L; (2) trivalent iron ion 5.0 to 8,000 mg / L; and (3) aluminum ion; divalent iron ion: 3
- the ratio of iron ions of valence is preferably 4,900: 2,000 or less.
- a bivalent iron ion is 0.5 or less with respect to 1 trivalent iron ion.
- the deep sea water concentration composition deep sea water, dried sea water, and flower extracts of hot water may be simply referred to as "minerals”.
- the concentration of the insertable mineral is improved as compared with the conventional one. Containing about 0.0001% to about 5%, for example, about 0.1% to about 5%, about 2% to about 5%, about 3% to about 5%, by weight of the total weight of the vesicle Can do.
- the cationized vesicle of the present invention can contain various substances.
- vitamin C derivatives for example, sodium ascorbyl phosphate
- the concentration of the vitamin C derivative can be about 0.1% to about 5% by weight based on the total weight of the vesicles.
- the active ingredient-encapsulated vesicle is an active ingredient (eg, minerals, amino acids, anionic surfactant, vitamin C and its derivatives, etc.) to be contained at a temperature of about 80 ° C.
- the cationized polymer After stirring and mixing the cationized polymer, the phospholipid, the surfactant, and optionally the other cosmetic ingredients and the aqueous solvent (purified water or seawater), they are gradually cooled to about room temperature to about 35 ° C. be able to. In addition, it can manufacture suitably using the publicly known art as a manufacturing method of the above-mentioned liposome.
- the cooled composition may be further emulsified at high pressure (eg 220 MPa ⁇ 5 Pass) and filtered (eg filtered with a 1.0 ⁇ m filter).
- Said other cosmetic ingredients include moisturizing ingredients, herbal extract, tyrosinase, enzymes such as superoxide dismutase, lipase, retinol, ascorbic acid, tocopherol, pyridoxal, vitamins such as riboflavin and derivatives thereof, ⁇ -carotene, chlorophyll
- Such organic dyes glycerin, sorbitol, urea, lactic acid, propylene glycol, polyethylene glycol and copolymers, moisture components such as glucose derivatives, etc., paraffin, stearyl alcohol, cetyl alcohol, squalane, silicone oil, stearis etc.
- Such emollient ingredients, treatment ingredients, dandruff control ingredients, hair growth, hair growth ingredients, ultraviolet light absorbers, antioxidants, perfumes, preservatives, etc. can be mentioned. These may be used in combination of 2 or more types as needed.
- the cosmetic composition of the present invention can be produced by adding one or more active ingredient-containing cationized vesicles to a conventional lotion, cosmetic solution, milk, cream, shampoo or the like.
- the form of the cosmetic is not particularly limited, but it is preferably used by being applied to skin or hair. Applying topically for use also includes rinsing after application to the skin or hair.
- a cleansing agent, a cleansing agent, a lotion, a cosmetic liquid, a pack, a massage cream, an emulsion, a moisturizing cream, a lip cream, etc. a makeup cosmetic, a foundation, a white powder, a lipstick, a blush, an eye shadow, etc.
- Soaps, liquid detergents, bath additives, etc., hair care cosmetics such as shampoos, rinses, hair treatments, hair setting agents, hair tonics, hair restorers, scalp treatments, etc.
- various cosmetic ingredients oil and fats, waxes, hydrocarbons, fatty acids, alcohols, esters, amino acids, vitamins
- surfactant pH adjuster, preservative, fragrance, moisturizer, powder, UV absorber, thickener, pigment, antioxidant, skin lightening agent, anti-inflammatory agent, anti-wrinkle agent, skin roughening agent, acne Drugs, alkalis, chelating agents, sequestering agents, etc.
- the cosmetic of the present invention may contain substances derived from natural products.
- substances derived from natural products are: Ume extract described in Patent No. 4795475, for example, Ume root extract and Ume fruit distilled water.
- JP-A-2012-116761 describes water vapor distillation of plant-derived steam distilled water, for example, one or more plants selected from passion fruit, shimomikan, banana, atemoya, plume, tankan, lemon lime, ginger water.
- Example 1 Preparation of a cationized polymer Dissolve MPC: 16.6 g, Blemmer (registered trademark) QA; 33.4 g in water; 200 g in a four-necked flask, blow nitrogen for 30 minutes, and then, at 75 ° C, start the polymerization initiator (VA-061, Wako Pure Chemical Industries, Ltd. ) An industrial product (0.55 g) was added and allowed to polymerize for 10 hours. The polymerization solution was added dropwise to 5 liters of diethyl ether with stirring, and the deposited precipitate was filtered and vacuum dried at room temperature for 48 hours to obtain 30.1 g of cationized polymer powder.
- Blemmer registered trademark
- VA-061 Wako Pure Chemical Industries, Ltd.
- Example 2 Preparation of mineral-encapsulated cationized vesicle and evaluation of stability
- Mineral encapsulated cationized vesicles were made from the following materials. Hydrogenated cyclic lysophosphatidic acid Na / hydrogenated lecithin / cholesterol: 1%; A chelating agent that dissolves the inclusions (indicated as "mineral” in Table 1) and the inclusions; Various cationic polymers prepared in Example 1: 3%; Cocoyl Arginine Ethyl PCA as Preservative: 0.02% Mineral (hot spring flower extract) was used as an inclusion as an example of the raw material charged to the negative ion.
- the stability was evaluated on mineral-encapsulated cationized vesicles composed of various cationized polymers in which 0.01% to 1% of mineral (hot spring flower extract) was encapsulated using a chelating agent.
- the Z potential fluctuation in the presence or absence of cationized material by polyquaternium-64 was measured. Aggregation and precipitation were determined visually. The results are shown in Table 1. With regard to the particle size, it was judged that the particle size is larger (the particle size is larger) when the Z average or the scattering intensity first peak is 200 nm or more.
- Example 3 Storage Method by Freeze-Drying of Mineral-Encapsulated Cationized Vesicles
- 10% cluster dextrin (registered trademark) (hyperbranched cyclic dextrin) and purified water were mixed at a ratio of 1: 3: 6 with the mineral-encapsulated cationized vesicle prepared in Example 2 and stirred. Thereafter, it was frozen at -20.degree. C. or lower and freeze-dried.
- the particle size is the zeta potential both in the undiluted solution of mineral-encapsulated cationized vesicles and in the state before freezing mixed with 10% cluster dextrin (registered trademark) for lyophilization and in the state redissolved with purified water after lyophilization. Was kept stable. (Data not shown)
- Example 4 usefulness test
- Skin permeability and permeability tests were performed using fluorescent dyes as a substitute for inclusions.
- L acting from the stratum corneum side of EPISKIN was set to put PBS2mL TM -Large Model (EpiSkin), to 37 ° C. Culture for up to 6 hours and 24 hours. After action, it was rinsed with purified water, the skin was transferred to a tube with stainless steel beads and 1 mL of purified water, and the skin was crushed with TissueLyser.
- Example 5 Electron Microscopy
- Example 6 Patch test
- a patch tape coated with a cationized polymer, CSLV, CMLV an occlusion patch test was conducted for 24 hours by 20 Japanese.
- One hour after peeling off the patch tape using vaseline, physiological saline, and purified water as a negative subject the state of erythema is judged based on the negative subject and the following judgment criteria, and the skin stimulation is carried out using the following formula
- the index was calculated.
- the classification of the samples was performed based on the skin irritation index based on the following table.
- Skin irritation index total score / number of subjects ⁇ 100
- the aqueous phase A is heated to 75 ° C. and emulsified with an emulsifier. After cooling to 35 ° C., high pressure treatment (220 MPa ⁇ 5 passes) is performed to obtain a mineral-encapsulated cationized vesicle 1.
- the aqueous phase A is heated to 75 ° C. and emulsified with an emulsifier. After cooling to 35 ° C., high pressure treatment (220 MPa ⁇ 5 passes) is performed to obtain mineral-encapsulated cationized vesicle 2.
- the aqueous phase A is heated to 75 ° C. and emulsified with an emulsifier. After cooling to 35 ° C., high pressure treatment (220 MPa ⁇ 5 pass) is carried out to obtain a vitamin-containing cationized vesicle.
- the water phase A is heated to 75 ° C. and dissolved by stirring. Heat oil phase B to 85 ° C. and stir dissolve. Add cream to the water phase A, oil phase B, heat to 80 ° C. and emulsify with an emulsifier. Cool to 45 ° C. and neutralize by adding aqueous phase C. Cool to 35 ° C. and obtain a cream.
- the water phase A is heated to 75 ° C. and dissolved by stirring.
- the aqueous phase A is cooled to 40 ° C., pretreated B is added and stirred.
- the aqueous phase C is further added to neutralize. Cool to 35 ° C. to obtain a lotion.
- the water phase A is heated to 80 ° C. and dissolved by stirring. After cooling to 40 ° C., add aqueous phase B. Add cosmetic solution pretreatment C. After cooling to 35 ° C., a cosmetic solution is obtained.
- the water phase A is heated to 80 ° C. and dissolved by stirring. Add pre-treatments B and C, heat to 80 ° C., stir and dissolve. Heat oil phase E to 90 ° C. and stir dissolve. Add the oil phase E to the water phase A, heat to 80 ° C., and emulsify with an emulsifier. Cool to 45 ° C. and neutralize by adding aqueous phase F. Cool to 35 ° C. and obtain a cream.
- the water phase A is heated to 80 ° C. and dissolved by stirring. Cool to 40 ° C., add pretreatments B and C and stir. Add aqueous phase D to neutralize. Cool to 35 ° C. and get mineral lotion.
- the water phase A is heated to 80 ° C. and dissolved by stirring.
- the aqueous phase B is heated to 75 ° C., stirred and added.
- the aqueous phase C is heated to 60 ° C., stirred and added. After cooling to 40 ° C., add aqueous phase D. Cool to 35 ° C. and obtain a shampoo.
- the aqueous phase A is heated to 70 ° C. and dissolved by stirring. Heat oil phase B to 80 ° C. and stir dissolve. Add cream pretreatment B and oil phase B to the aqueous phase A, heat to 75 ° C. and emulsify with an emulsifier. Add aqueous phase C to neutralize. Cool to 40 ° C. and add aqueous phase D. Cool to 35 ° C. and get body milk.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
ベシクル(vesicle)は、両親媒性分子の水中での自発的な会合により、疎水性尾部を内側に、親水性頭部を外側に向けた二重層膜が閉じた球状の構造体として形成される。
カチオン化とは、物質をプラスに帯電させることである。カチオン化させたベシクルはプラスに帯電しているので、カチオン化されてないベシクルと比べて皮膚に吸着・浸透しやすくなることが期待される。本発明では、このような効果を得られる程度にベシクルをカチオン化させることが望ましい。具体的には、カチオン化されたベシクルのΖ(ゼータ)電位が+20mv以上、さらに好ましくは+30mV以上あると良い。カチオン化ベシクルのΖ電位は、保存のために賦形剤を加えて凍結乾燥し、その後に水性溶媒に再溶解した場合においても安定に保たれることが望ましい。本明細書では、MLVおよびSLVの両方を特に区別せずに、本発明の「カチオン化ベシクル」と称する。また、カチオン化MLVを「CMLV」、カチオン化SLVを「CSLV」と略称することもある。
ブレンマー(登録商標)QA: (2-ヒドロキシ-3-メタクリロイルオキシプロピル)トリメチルアンモニウムクロライド;
MOETAC: 2-(メタクリロイルオキシ)エチルトリメチルアンモニウムクロライド;
DMAEA(登録商標)-BQ: N,N-ジメチルアミノエチルアクリレート塩化ベンジル4級塩
などが挙げられる。
化粧品有効成分を内包させたカチオン化ベシクルを、ローション、美容液、乳液、クリーム、シャンプーなどの化粧料に添加して使用すると、当該成分を皮膚に効率よく送達できる。
(1) 硫酸イオンを90%以上除去し得るナノフィルター膜で海洋深層水を処理して、Brixが2.8~3.6、Mgイオン濃度が300~900mg/L、Caイオン濃度が200~600mg/L、及びSO4イオン濃度が0~300mg/LであるNF膜透過水を得る工程;及び
(2) 工程(1)で得たNF膜透過水を濃縮して、Brixが30.0~55.0、Mgイオン濃度が10,000~100,000mg/L、Caイオン濃度が4,000~40,000mg/L、及びSO4イオン濃度が0~1,000mg/L、並びにCaイオン濃度:Mgイオン濃度 = 1:0.25~1:4である、NF膜透過水濃縮物を得る工程。
(1) 温泉の噴気を、青粘土上で、一定温度及び一定湿度で結晶化させて湯の花を得て、
(2) 湯の花を水性溶媒に溶解し、そして
(3) 溶解物をオゾン酸化処理して、オゾン酸化処理物を得る。
MPC;16.6g、ブレンマー(登録商標)QA;33.4gを水;200gに溶解し4つ口フラスコに入れ、30分間窒素を吹き込んだ後、75℃で重合開始剤(VA-061、和光純薬工業製、0.55g)を加えて10時間重合反応させた。重合液を5リットルのジエチルエーテル中に攪拌しながら滴下し、析出した沈殿をろ過し、48時間室温で真空乾燥を行って、カチオン化ポリマー粉末30.1gを得た。これにより、分子量70万、MPC45%とブレンマー(登録商標)QA55%(MPC/カチオン=45/55)からなるカチオン化ポリマー(ポリクオタニウム-64)を得た。また、同様の方法で、分子量およびMPCとブレンマーQAの割合の違うカチオン化ポリマーおよび、MPCとMOETACもしくはDMAEQ-BQからなるカチオンモノマーの違うカチオン化ポリマーを得た。
ミネラル内包カチオン化ベシクルを、以下の物質から作製した。
水添環状リゾフォスファチジン酸Na/水添レシチン/コレステロール:1%;
内包物(表1で「ミネラル」と表示)と内包物を溶解させるキレート剤;
実施例1で作製した各種カチオン化ポリマー:3%;
防腐剤としてココイルアルギニンエチルPCA:0.02%
マイナスイオンに帯電している原料の例として、ミネラル(湯の花抽出物)を内包物として用いた。0.01%~1%のミネラル(湯の花抽出物)を、キレート剤を用いて内包させた、各種カチオン化ポリマーからなるミネラル内包カチオン化ベシクルについて安定性を評価した。ポリクオタニウム-64によるカチオン化物質の有無におけるZ電位変動を測定した。凝集・沈澱は目視で判定した。結果を表1に示す。粒径については、Z平均もしくは散乱強度第1ピークが200nm以上だと粒径が大きめである(粒径大)と判断した。
実施例2で作製したミネラル内包カチオン化ベシクルに10%クラスターデキストリン(登録商標)(高度分岐環状デキストリン)、精製水を1:3:6の割合で混合し、攪拌した。その後、-20℃以下で凍結し、凍結乾燥を行った。
内包物の代替として蛍光色素を用いて、皮膚浸透性・透過性試験を実施した。0.01%カルセインおよび0.01%カルセインを内包したSLV、MLV、CSLV、CMLVを、12 well plateにPBS2mLを入れてセットしたEpiSkinTM-Large Model (EpiSkin)の角層側から300 μL作用させ、37℃にて6時間および24時間まで培養した。作用後、精製水でリンスし、ステンレスビーズおよび精製水1mLとともに皮膚をチューブに移し、TissueLyserにて皮膚を粉砕した。遠心分離で上清を取得し、蛍光強度(Ex/Em=494/520nm)を測定して、皮膚中のカルセイン量を算出し、皮膚浸透効果を評価した。また、12 well plateのPBSも同様に蛍光強度(Ex/Em=494/520nm)を測定して、皮膚透過効果を評価した。
SLV、MLV、CSLV、CMLVについて、透過型電子顕微鏡で観察を行った。SLV、CSLVは単層、MLV、CMLVは多層構造を有している事が確認された。
カチオン化ポリマー、CSLV、CMLVを塗布したパッチテープを用いて、日本人20名で24時間閉塞パッチテストを行った。陰性対象として、ワセリン、生理食塩水、精製水を用いて、パッチテープを剥がした1時間後に、紅斑の状態を陰性対象および以下の判定基準に照らして判定を行い、次式を用いて皮膚刺激指数を算出した。検体の分類は、皮膚刺激指数からを以下の表を元に行った。
皮膚刺激指数=評点総和/被験者数×100
水相Aを75℃まで加熱し、攪拌溶解する。
油相Bを85℃まで加熱し、攪拌溶解する。
水相Aにクリーム、油相Bを加え、80℃まで加熱し、乳化機で乳化する。
45℃まで冷却し、水相Cを加えて中和する。
35℃まで冷却し、クリームを得る。
水相Aを80℃まで加熱し、攪拌溶解する。
前処理B、Cを加え、80℃まで加熱し、攪拌溶解する。
油相Eを90℃まで加熱し、攪拌溶解する。
水相Aに油相Eを加え、80℃まで加熱し、乳化機で乳化する。
45℃まで冷却し、水相Fを加えて中和する。
35℃まで冷却し、クリームを得る。
水相Aを80℃まで加熱し、攪拌溶解する。
水相Bを75℃まで加熱し、攪拌溶解して加える。
水相Cを60℃まで加熱し、攪拌溶解して加える。
40℃まで冷却後、水相Dを加える。
35℃まで冷却し、シャンプーを得る。
Claims (11)
- 2-メタクリロイルオキシエチルホスホリルコリンとカチオンモノマーを含むカチオン化ポリマーでカチオン化させた、化粧品に添加して使用するためのカチオン化ベシクルであって、カチオン化ポリマー中のカチオンモノマーの割合が50%以上である、カチオン化ベシクル。
- 単層ベシクルまたは多層ベシクルである、請求項1に記載のカチオン化ベシクル。
- カチオンモノマーが、
(2-ヒドロキシ-3-メタクリロイルオキシプロピル)トリメチルアンモニウムクロライド、又は
2-(メタクリロイルオキシ)エチルトリメチルアンモニウムコロライド、又は
N,N-ジメチルアミノエチルアクリレート塩化ベンジル4級塩
である、請求項1又は2に記載のカチオン化ベシクル。 - 請求項1~3のいずれかに記載のカチオン化ベシクルに化粧品有効成分が保持された、有効成分内包カチオン化ベシクル。
- 前記有効成分がミネラルである、請求項4に記載の有効成分内包カチオン化ベシクル。
- 前記有効成分がビタミンCまたはビタミンC誘導体である、請求項4に記載の有効成分内包カチオン化ベシクル。
- Ζ電位が+20mV以上である、請求項1~3のいずれかに記載のカチオン化ベシクル、又は請求項4~6のいずれかに記載の有効成分内包カチオン化ベシクル。
- 凍結乾燥された、請求項1~3のいずれかに記載のカチオン化ベシクル、又は請求項4~6のいずれかに記載の有効成分内包カチオン化ベシクル。
- カチオン化ベシクルを含有する化粧料であって、該カチオン化ベシクルが請求項1~3のいずれかに記載のカチオン化ベシクル、又は請求項4~6のいずれかに記載の有効成分内包カチオン化ベシクル、又は請求項8に記載の凍結乾燥されたカチオン化ベシクル若しくは有効成分内包カチオン化ベシクルである、化粧料。
- 皮膚および毛髪への吸着性を有し、局所的に塗布される、請求項9に記載の化粧料。
- 請求項9に記載の化粧料を皮膚又は毛髪に塗布することを含む、美容施術方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780097571.3A CN111683650B (zh) | 2017-12-08 | 2017-12-08 | 阳离子化囊泡及其组合物 |
PCT/JP2017/044249 WO2019111415A1 (ja) | 2017-12-08 | 2017-12-08 | カチオン化ベシクル及びその組成物 |
JP2019557977A JP6735426B2 (ja) | 2017-12-08 | 2017-12-08 | カチオン化ベシクル及びその組成物 |
EP17934057.5A EP3721866A4 (en) | 2017-12-08 | 2017-12-08 | CATIONIZED VESICLE, AND ASSOCIATED COMPOSITION |
KR1020207018915A KR102281703B1 (ko) | 2017-12-08 | 2017-12-08 | 카티온화 베시클 및 그 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2017/044249 WO2019111415A1 (ja) | 2017-12-08 | 2017-12-08 | カチオン化ベシクル及びその組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019111415A1 true WO2019111415A1 (ja) | 2019-06-13 |
Family
ID=66750856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/044249 WO2019111415A1 (ja) | 2017-12-08 | 2017-12-08 | カチオン化ベシクル及びその組成物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3721866A4 (ja) |
JP (1) | JP6735426B2 (ja) |
KR (1) | KR102281703B1 (ja) |
CN (1) | CN111683650B (ja) |
WO (1) | WO2019111415A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114514012A (zh) * | 2019-10-15 | 2022-05-17 | 株式会社高丝 | 皮肤外用剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102439800B1 (ko) * | 2020-09-10 | 2022-09-02 | 주식회사 엔에프씨 | 오징어 먹물 성분을 함유하는 나노 리포좀 구조 및 이를 활용한 염모제 조성물 |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5220546B2 (ja) | 1975-08-04 | 1977-06-04 | ||
JPS544505B2 (ja) | 1973-11-05 | 1979-03-07 | ||
JPS5623076B2 (ja) | 1973-04-17 | 1981-05-28 | ||
JPH06178930A (ja) * | 1992-12-15 | 1994-06-28 | Pola Chem Ind Inc | 被膜安定化リポソーム及びその製造方法 |
JP2526362B2 (ja) | 1993-09-29 | 1996-08-21 | ワミレスコスメティックス株式会社 | 化粧料 |
JP2000290159A (ja) | 1999-04-05 | 2000-10-17 | Wamiles Cosmetics Kk | 化粧品 |
JP2005336127A (ja) * | 2004-05-28 | 2005-12-08 | Doctor Program Kk | 皮膚外用剤 |
JP2006035036A (ja) | 2004-07-23 | 2006-02-09 | Kao Corp | 油性薬剤含有粒子 |
JP2007176821A (ja) | 2005-12-27 | 2007-07-12 | Nippon Fine Chem Co Ltd | 粉末状リン脂質組成物 |
JP2007176820A (ja) | 2005-12-27 | 2007-07-12 | Nippon Fine Chem Co Ltd | 粉末状リン脂質組成物 |
JP3967357B2 (ja) | 2005-01-12 | 2007-08-29 | ワミレスコスメティックス株式会社 | 皮膚外用用組成物及びそれを用いた美容施術方法 |
JP2007217356A (ja) | 2006-02-17 | 2007-08-30 | Wamiles Cosmetics Kk | 海洋深層水濃縮物含有組成物及びその製造方法 |
JP2009029788A (ja) | 2007-06-22 | 2009-02-12 | Wamiles Cosmetics Kk | 海水由来酵母培養物含有皮膚外用用組成物 |
WO2010067617A1 (ja) * | 2008-12-12 | 2010-06-17 | 国立大学法人 北海道大学 | 脂質膜構造体 |
JP4795475B1 (ja) | 2010-04-15 | 2011-10-19 | ワミレスコスメティックス株式会社 | ウメ抽出物を含む剤 |
JP4950419B2 (ja) | 2004-05-25 | 2012-06-13 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | 細胞内浸透を促進するカチオン性ポリマーを含むリポソーム |
JP2012116761A (ja) | 2010-11-29 | 2012-06-21 | Wamiles Cosmetics Kk | 植物由来水蒸気蒸留含有化粧料 |
JP2012184182A (ja) * | 2011-03-04 | 2012-09-27 | Nof Corp | 化粧料用リポソーム及び化粧料 |
JP2012206948A (ja) | 2011-03-29 | 2012-10-25 | Kose Corp | リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法 |
JP2015189762A (ja) * | 2014-03-30 | 2015-11-02 | 小林製薬株式会社 | 水中油型乳化組成物 |
JP2016108285A (ja) | 2014-12-08 | 2016-06-20 | ワミレスコスメティックス株式会社 | カチオン化ベシクル及びその組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4610391B2 (ja) * | 2005-03-30 | 2011-01-12 | ピアス株式会社 | カチオン型高分子ミセル薬物担体を配合した皮膚外用剤、化粧料 |
KR101272741B1 (ko) * | 2005-10-18 | 2013-06-10 | (주)아모레퍼시픽 | 유용성 활성물질 안정화 양이온성 고분자 나노캡슐 및 이의제조방법, 및 이를 함유하는 화장료 조성물 |
CA2688812A1 (en) * | 2007-05-21 | 2008-11-27 | Aquea Scientific Corporation | Highly charged microcapsules |
EP2512416A2 (fr) * | 2009-12-18 | 2012-10-24 | L'Oréal | Procédé de traitement cosmétique impliquant un composé apte à condenser in situ |
ES2373704B1 (es) * | 2010-02-18 | 2013-01-24 | Lipotec S.A. | Liposomas para el tratamiento de materiales textiles. |
DE102011076149A1 (de) * | 2011-05-19 | 2012-11-22 | Rovi Cosmetics International Gmbh | Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare |
JP6559994B2 (ja) * | 2015-03-27 | 2019-08-14 | 株式会社コーセー | 毛髪化粧料 |
US20170042784A1 (en) * | 2015-08-10 | 2017-02-16 | Air Products And Chemicals, Inc. | Composition for penetrating sugar based delivery system |
-
2017
- 2017-12-08 KR KR1020207018915A patent/KR102281703B1/ko active IP Right Grant
- 2017-12-08 WO PCT/JP2017/044249 patent/WO2019111415A1/ja unknown
- 2017-12-08 CN CN201780097571.3A patent/CN111683650B/zh active Active
- 2017-12-08 JP JP2019557977A patent/JP6735426B2/ja active Active
- 2017-12-08 EP EP17934057.5A patent/EP3721866A4/en active Pending
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5623076B2 (ja) | 1973-04-17 | 1981-05-28 | ||
JPS544505B2 (ja) | 1973-11-05 | 1979-03-07 | ||
JPS5220546B2 (ja) | 1975-08-04 | 1977-06-04 | ||
JPH06178930A (ja) * | 1992-12-15 | 1994-06-28 | Pola Chem Ind Inc | 被膜安定化リポソーム及びその製造方法 |
JP2526362B2 (ja) | 1993-09-29 | 1996-08-21 | ワミレスコスメティックス株式会社 | 化粧料 |
JP2000290159A (ja) | 1999-04-05 | 2000-10-17 | Wamiles Cosmetics Kk | 化粧品 |
JP4950419B2 (ja) | 2004-05-25 | 2012-06-13 | ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス | 細胞内浸透を促進するカチオン性ポリマーを含むリポソーム |
JP2005336127A (ja) * | 2004-05-28 | 2005-12-08 | Doctor Program Kk | 皮膚外用剤 |
JP2006035036A (ja) | 2004-07-23 | 2006-02-09 | Kao Corp | 油性薬剤含有粒子 |
JP3967357B2 (ja) | 2005-01-12 | 2007-08-29 | ワミレスコスメティックス株式会社 | 皮膚外用用組成物及びそれを用いた美容施術方法 |
JP2007176821A (ja) | 2005-12-27 | 2007-07-12 | Nippon Fine Chem Co Ltd | 粉末状リン脂質組成物 |
JP2007176820A (ja) | 2005-12-27 | 2007-07-12 | Nippon Fine Chem Co Ltd | 粉末状リン脂質組成物 |
JP2007217356A (ja) | 2006-02-17 | 2007-08-30 | Wamiles Cosmetics Kk | 海洋深層水濃縮物含有組成物及びその製造方法 |
JP2009029788A (ja) | 2007-06-22 | 2009-02-12 | Wamiles Cosmetics Kk | 海水由来酵母培養物含有皮膚外用用組成物 |
WO2010067617A1 (ja) * | 2008-12-12 | 2010-06-17 | 国立大学法人 北海道大学 | 脂質膜構造体 |
JP4795475B1 (ja) | 2010-04-15 | 2011-10-19 | ワミレスコスメティックス株式会社 | ウメ抽出物を含む剤 |
JP2012116761A (ja) | 2010-11-29 | 2012-06-21 | Wamiles Cosmetics Kk | 植物由来水蒸気蒸留含有化粧料 |
JP2012184182A (ja) * | 2011-03-04 | 2012-09-27 | Nof Corp | 化粧料用リポソーム及び化粧料 |
JP2012206948A (ja) | 2011-03-29 | 2012-10-25 | Kose Corp | リポソーム組成物、並びにそれを用いた化粧料、皮膚外用剤及びその製造方法 |
JP2015189762A (ja) * | 2014-03-30 | 2015-11-02 | 小林製薬株式会社 | 水中油型乳化組成物 |
JP2016108285A (ja) | 2014-12-08 | 2016-06-20 | ワミレスコスメティックス株式会社 | カチオン化ベシクル及びその組成物 |
Non-Patent Citations (11)
Title |
---|
ARCH. BIOCHEM. BIOPHYS., vol. 212, 1981, pages 186 |
BANGHAM ET AL., J. MOL. BIOL., vol. 13, 1965, pages 238 |
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 94, 1980, pages 1367 |
BIOCHIM. BIOPHYS. ACTA, vol. 394, 1978, pages 483 |
BIOCHIM. BIOPHYS. ACTA, vol. 455, 1976, pages 322 |
FEBS LETT., vol. 99, 1979, pages 210 |
J. CELL. BIOL., vol. 66, 1975, pages 621 |
N. Y. ACAD. SCI., vol. 308, 1978, pages 250 |
PROC. N. A. S. USA, vol. 75, 1978, pages 4194 |
See also references of EP3721866A4 * |
THIRD US-JAPAN SYMPOSIUM ON DRUG DELIVERY SYSTEM, 1995 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114514012A (zh) * | 2019-10-15 | 2022-05-17 | 株式会社高丝 | 皮肤外用剂 |
KR20220082876A (ko) | 2019-10-15 | 2022-06-17 | 가부시키가이샤 코세 | 피부외용제 |
Also Published As
Publication number | Publication date |
---|---|
CN111683650A (zh) | 2020-09-18 |
EP3721866A4 (en) | 2021-07-28 |
JP6735426B2 (ja) | 2020-08-05 |
JPWO2019111415A1 (ja) | 2020-04-02 |
KR102281703B1 (ko) | 2021-07-23 |
EP3721866A1 (en) | 2020-10-14 |
CN111683650B (zh) | 2021-11-05 |
KR20200098560A (ko) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4758915B2 (ja) | 多重層リポソームおよびその製造方法 | |
TWI508750B (zh) | 經膠原修飾之脂質體所成化妝料基劑及含有此之皮膚化妝料 | |
Pinto et al. | Niosomes as nano-delivery systems in the pharmaceutical field | |
JP6588568B2 (ja) | バイセル構造体を含有する組成物 | |
US10426715B2 (en) | Liposome composition | |
KR20070081192A (ko) | 오리자놀, 미강유 및 인지질이 내포된 리포좀을유효성분으로 함유하는 화장료 조성물 | |
CN111544317B (zh) | 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用 | |
KR100785484B1 (ko) | 고농도의 이데베논을 나노캡슐화한 기제 조성물, 이의제조방법 및 이를 함유한 화장료 | |
CN107405279A (zh) | 含有水凝胶的化妆品 | |
JP2002501879A (ja) | 皮膚細胞の再生および刺激のためのアルテミアサリナ抽出物に基づく化粧品 | |
JP6735426B2 (ja) | カチオン化ベシクル及びその組成物 | |
KR101594687B1 (ko) | 천연 리포좀 및 그 제조방법 | |
WO2018020903A1 (ja) | 皮膚外用剤 | |
KR100757043B1 (ko) | 유용성 활성성분의 피부 흡수 증진을 위한 양이온성 고분자나노캡슐 및 이를 함유하는 화장료 조성물 | |
JP2016108285A (ja) | カチオン化ベシクル及びその組成物 | |
Bugaj | Intradermal delivery of active cosmeceutical ingredients | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
JP2023110365A (ja) | カチオン化ベシクル及びその組成物 | |
JP4592347B2 (ja) | 外用剤組成物 | |
CN114144159A (zh) | 包括死海提取物的纳米颗粒及其用途 | |
KR101702482B1 (ko) | 나노리포좀이 형성되어 피부면역력, 살균력 및 흡수력이 향상된 화장료 조성물 및 그 제조방법 | |
KR20150078137A (ko) | 주름 개선용 화장료 조성물의 제조방법 | |
US6077529A (en) | Active ingredient system and method of manufacture thereof for transfer of lipophilic and amphiphilic components to target structures | |
KR101808078B1 (ko) | 리조레시친 및 글리세로포스포콜린을 이용한 리포좀 제제, 및 이를 포함하는 퍼스널 케어 조성물 | |
RU2139041C1 (ru) | Гидратантный регенерирующий крем и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019557977 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17934057 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207018915 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017934057 Country of ref document: EP Effective date: 20200708 |